Brokerages Set Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Price Target at $35.80

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) has received an average rating of “Moderate Buy” from the six ratings firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $35.80.

Separately, HC Wainwright initiated coverage on shares of Kyverna Therapeutics in a report on Wednesday, July 3rd. They set a “neutral” rating and a $8.00 price target for the company.

Kyverna Therapeutics Stock Up 7.6 %

NASDAQ KYTX opened at $8.23 on Wednesday. Kyverna Therapeutics has a 52 week low of $6.75 and a 52 week high of $35.06. The business’s 50 day moving average price is $11.84.

Kyverna Therapeutics (NASDAQ:KYTX) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($1.12) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.28). During the same period in the prior year, the business posted ($12.10) EPS. As a group, research analysts expect that Kyverna Therapeutics will post -3.6 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Bain Capital Life Sciences Investors LLC acquired a new stake in Kyverna Therapeutics during the 1st quarter worth $78,590,000. Jennison Associates LLC acquired a new stake in Kyverna Therapeutics during the 1st quarter worth $34,743,000. Price T Rowe Associates Inc. MD acquired a new stake in Kyverna Therapeutics during the 1st quarter worth $23,093,000. Janus Henderson Group PLC acquired a new stake in Kyverna Therapeutics during the 1st quarter worth $15,041,000. Finally, Avoro Capital Advisors LLC acquired a new stake in Kyverna Therapeutics during the 1st quarter worth $11,799,000. Institutional investors and hedge funds own 18.08% of the company’s stock.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.